AIO-GC-0121/ass - SAKK 01/18 Radio-Chemotherapie mit reduzierter Intensität bei Patienten mit einem Seminom (Hodenkrebs) des Stadiums IIA/B. Eine multizentrische, offene Phase-II-Studie mit zwei Patientengruppen (Aktiv)
SAKK 01/18 Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma (Aktiv)
TITAN TCC TITAN-TCC (0416-ASG) is a Phase 2, open-label study of nivolumab (BMS-936558) monotherapy with additional nivolumab/ipilimumab "boost" cycles in previously untreated and platinum-based pretreated, 2nd and 3rd line, advanced or metastatic transitional cell carcinoma subjects. Nivolumab is a fully human PD-1 antibody which blocks the respective immune checkpoint in a ligand (PD-L1/PD-L2) independent manner. (Aktiv)